Armata Pharmaceuticals (ARMP) Amount of Cash per Share

Symbol and logo of brand Armata (ARMP)

Armata Pharmaceuticals (ARMP) develops treatments against resistant bacteria in US laboratories. The GURU.Markets platform tracks the cash per share trend, where 0.49 indicates the value of this parameter. High demand is driven by a unique platform of targeted phages that eliminate infections. Current viability relies on external capital and scientific potential until clinical trials are completed.

Cash per Share: Armata Pharmaceuticals, Inc. (ARMP) for 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for armatapharma.com (ARMP)

- price and consensus price forecast:
- cash and cash flow data:
General company analysis:Armata - ARMP
Finished products of Armata Pharmaceuticals

For Armata Pharmaceuticals (ARMP), which is developing innovative phage therapies against superbugs, this metric reflects the actual amount of liquidity per share net of all liabilities. By analyzing the quarterly trend of cash per share, an investor assesses the biotech brand's financial resilience against cash flow gaps, where growth in this metric confirms the availability of resources to complete costly clinical trials.

Analysis of competing companies